Brinker T, Seifert V, Dietz H
Neurosurgical Department, Medical School, Hannover, Germany.
Neurosurgery. 1992 Aug;31(2):306-11; discussion 311-2. doi: 10.1227/00006123-199208000-00016.
It is investigated whether intrathecal fibrinolysis may prevent subacute hydrocephalus after subarachnoid hemorrhage (SAH). In 19 cats, SAH was induced by the intracisternal infusion of 1 ml/kg body weight of fresh autologous blood at a rate of 0.6 ml/min. Eleven of those animals were treated by intrathecal fibrinolysis performed 24 hours after experimental SAH by intracisternal infusion of 3 mg of recombinant tissue plasminogen activator. Included were eight animals suffering from experimental SAH and four healthy animals retained for control. A computed tomographic scan performed 24 hours after the SAH displayed an acute hydrocephalus from the experimental procedure. Cerebrospinal fluid outflow resistance was 71 +/- 5.0 mm Hg/ml/min in the healthy animals, 265 +/- 19.8 mm Hg/ml/min in the nontreated animals 7 days after SAH, and 151 +/- 6.4 mm Hg/ml/min in the recombinant tissue plasminogen activator-treated animals 7 days after SAH (mean +/- standard deviation; changes significant with P less than 0.01). Postmortem planimetry of both lateral ventricles gives a mean of 3.7 +/- 2.7 mm2 in the healthy animals, 11.1 +/- 3.9 mm2 in the nontreated group after SAH (P less than 0.01), and 3.5 +/- 1.1 mm2 in the animals treated with recombinant tissue plasminogen activator. Intracranial pressure monitoring demonstrated marked intracranial pressure waves only in the nontreated animals after SAH. It is concluded that intrathecal fibrinolysis may prevent subacute hydrocephalus after experimental SAH.
研究了鞘内注射纤维蛋白溶解剂是否可预防蛛网膜下腔出血(SAH)后的亚急性脑积水。在19只猫中,通过脑池内以0.6 ml/min的速度注入1 ml/kg体重的新鲜自体血诱导SAH。其中11只动物在实验性SAH 24小时后通过脑池内注入3 mg重组组织型纤溶酶原激活剂进行鞘内纤维蛋白溶解治疗。包括8只患有实验性SAH的动物和4只作为对照的健康动物。SAH后24小时进行的计算机断层扫描显示实验过程导致急性脑积水。健康动物的脑脊液流出阻力为71±5.0 mmHg/ml/min,SAH后7天未治疗动物为265±19.8 mmHg/ml/min,SAH后7天重组组织型纤溶酶原激活剂治疗动物为151±6.4 mmHg/ml/min(平均值±标准差;P<0.01时变化显著)。双侧侧脑室的死后平面测量显示,健康动物平均为3.7±2.7 mm²,SAH后未治疗组为11.1±3.9 mm²(P<0.01),重组组织型纤溶酶原激活剂治疗动物为3.5±1.1 mm²。颅内压监测显示,SAH后仅在未治疗动物中出现明显的颅内压波。得出的结论是,鞘内纤维蛋白溶解可能预防实验性SAH后的亚急性脑积水。